Key Highlights

  • The first patient-specific ROXUS prescriptions received through the Mavrox telehealth platform have been fulfilled in the US.
  • Strive Pharmacy compounds and fulfils the prescriptions, with Mavrox acting as the direct-to-consumer route.
  • The company has not disclosed prescription numbers or Revenue from the first fulfilments.
  • ROXUS is a compounded medication and is not reviewed or approved by the FDA for safety or efficacy.

LTR Pharma Limited (ASX:LTP) has announced that the first patient-specific ROXUS prescriptions received through Mavrox, the men's health telehealth platform operated by Shed, have been fulfilled in the United States. The company describes the event as the start of ROXUS prescription activity under its agreements with Shed and Strive Pharmacy, and says it follows completion of the operational work needed to support fulfilment.

How the US Route Works

Mavrox provides the initial US direct-to-consumer telehealth route for ROXUS, and Strive Pharmacy supports compounding and fulfilment. The company states that Strive has set up the operational systems needed to receive, compound and fulfil valid patient-specific ROXUS prescriptions. ROXUS is LTR Pharma's intranasal medication for erectile dysfunction support, compounded and dispensed in the United States by a licensed pharmacy under the patient-specific compounding provisions of Section 503A of the US Federal Food, Drug, and Cosmetic Act.

Executive Chairman Lee Rodne said the company has moved from implementation to serving patients under these arrangements, and noted that the milestone came less than three months after the agreement with Shed was announced.

Regulatory Position

The announcement states that ROXUS is a compounded medication prepared for identified individual patient needs based on a valid prescription from a prescribing healthcare practitioner. As such, it is not reviewed or approved by the US Food and Drug Administration for safety or efficacy. Compounded drugs are intended for patients whose prescriber has determined that their medical needs are not met by an available FDA-approved drug. The statements have not been evaluated by the FDA, and prescribers are expected to use independent clinical judgement when deciding whether the product is appropriate for individual patients.

What Has Not Been Disclosed

The announcement does not state how many prescriptions have been fulfilled, what revenue they generate, the price charged or the terms of the revenue arrangement with Shed or Strive Pharmacy. The company says it will provide further updates on US prescription activity as meaningful information becomes available. Its stated focus is on supporting its US partners as prescribing and prescription activity builds, which means volumes depend on prescriber and patient uptake through the Mavrox platform. The announcement also contains forward-looking statements on ongoing US prescription activity and fulfilment, and notes that these involve risks and assumptions beyond the company's control, so actual results may differ materially.

Company Background

LTR Pharma describes itself as a commercial-stage pharmaceutical company with a proprietary intranasal drug-delivery platform. It says it has commercialised its rapid-acting technology in Australia and is expanding access while advancing regulatory pathways in the US and other key markets. Its lead products, SPONTAN and ROXUS, are fast-acting intranasal sprays for erectile dysfunction, with onset of action in 10 minutes or less according to the company. It is also advancing OROFLOW, an intranasal spray under development for oesophageal motility disorders.

Where the Rollout Stands

The first fulfilments confirm that the telehealth and pharmacy chain is operating, but the announcement provides no Volume or revenue figures, and the compounded status of the product means it sits outside FDA review. Future updates on prescription activity, the pace of prescribing through Mavrox and any change in the regulatory pathway will shape how the US channel develops.